[kragen]

In the comment you responded to, I am not taking up the subject of how to achieve testing, replication, QC, and transparency. I am merely pointing out that, to reason clearly about the issue, it is essential to distinguish these goods—genuinely valuable benefits to drug users which should be maximized—from any potential means for achieving them, such as regulatory compliance, which is a deadweight loss to be minimized, even if it is an unavoidable one, as you claim it is.

To do otherwise is similar to measuring the progress of a software project in lines of code, measuring the quality of an airframe design by its weight, or measuring the security provided by the TSA in the number of fingernail trimmers confiscated. It's counting regulatory compliance activities on the wrong side of the ledger.